KoBioLabs고바이오랩
348150 · KOSDAQ · ₩348150 · 고바이오랩
₩2,720 ₩0 (0.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩69B | ₩68B | ₩33B | ₩12B | ₩2.9B |
| Cost of sales | ₩18B | ₩22B | ₩9.4B | ₩3.6B | ₩984M |
| Gross profit | ₩51B | ₩47B | ₩24B | ₩8B | ₩1.9B |
| Operating income | −₩9.7B | −₩6.9B | −₩18B | −₩20B | −₩16B |
| Net income | −₩7B | −₩4.6B | −₩15B | −₩23B | −₩15B |
| Net income to shareholders | −₩6.3B | −₩5.3B | −₩14B | −₩22B | −₩15B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩91B | ₩102B | ₩115B | ₩124B | ₩105B |
| Current assets | ₩60B | ₩67B | ₩76B | ₩102B | ₩99B |
| Cash and equivalents | ₩4.6B | ₩5.7B | ₩10B | ₩10B | ₩53B |
| Total liabilities | ₩42B | ₩47B | ₩53B | ₩28B | ₩15B |
| Current liabilities | ₩13B | ₩14B | ₩21B | ₩8.9B | ₩6.8B |
| Borrowings | ₩13B | ₩16B | ₩9.2B | ₩6B | ₩2.4B |
| Total equity | ₩49B | ₩55B | ₩62B | ₩95B | ₩91B |
| Shareholders' equity | ₩32B | ₩38B | ₩45B | ₩77B | ₩91B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.8B | −₩4.4B | −₩14B | −₩17B | −₩12B |
| Capital spending | ₩297M | ₩1.6B | ₩15B | ₩15B | ₩5.5B |
| Free cash flow | −₩6.1B | −₩6B | −₩29B | −₩31B | −₩18B |
Consolidated where available. Amounts in won.
Also known as: KoBioLabs / 고바이오랩 / 348150 / KRX:348150
Source: KRX statistical information